Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners.

Autor: Woods A; University of Canberra, Research Institute for Sport and Exercise, Canberra, Australia., Garvican-Lewis LA; University of Canberra, Research Institute for Sport and Exercise, Canberra, Australia; Australian Institute of Sport, Canberra, Australia., Saunders PU; Australian Institute of Sport, Canberra, Australia., Lovell G; Australian Institute of Sport, Canberra, Australia., Hughes D; Australian Institute of Sport, Canberra, Australia., Fazakerley R; Australian Institute of Sport, Canberra, Australia., Anderson B; Australian Institute of Sport, Canberra, Australia., Gore CJ; Australian Institute of Sport, Canberra, Australia., Thompson KG; University of Canberra, Research Institute for Sport and Exercise, Canberra, Australia.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2014 Sep 23; Vol. 9 (9), pp. e108042. Date of Electronic Publication: 2014 Sep 23 (Print Publication: 2014).
DOI: 10.1371/journal.pone.0108042
Abstrakt: Purpose: To determine the effect of intravenous iron supplementation on performance, fatigue and overall mood in runners without clinical iron deficiency.
Methods: Fourteen distance runners with serum ferritin 30-100 µg · L(-1) were randomly assigned to receive three blinded injections of intravenous ferric-carboxymaltose (2 ml, 100 mg, IRON) or normal saline (PLACEBO) over four weeks (weeks 0, 2, 4). Athletes performed a 3,000 m time trial and 10 × 400 m monitored training session on consecutive days at week 0 and again following each injection. Hemoglobin mass (Hbmass) was assessed via carbon monoxide rebreathing at weeks 0 and 6. Fatigue and mood were determined bi-weekly until week 6 via Total Fatigue Score (TFS) and Total Mood Disturbance (TMD) using the Brief Fatigue Inventory and Brunel Mood Scale. Data were analyzed using magnitude-based inferences, based on the unequal variances t-statistic and Cohen's Effect sizes (ES).
Results: Serum ferritin increased in IRON only (Week 0: 62.8 ± 21.9, Week 4: 128.1 ± 46.6 µg · L(-1); p = 0.002) and remained elevated two weeks after the final injection (127.0 ± 66.3 µg · L(-1), p = 0.01), without significant changes in Hbmass. Supplementation had a moderate effect on TMD of IRON (ES -0.77) with scores at week 6 lower than PLACEBO (ES -1.58, p = 0.02). Similarly, at week 6, TFS was significantly improved in IRON vs. PLACEBO (ES -1.54, p = 0.05). There were no significant improvements in 3,000 m time in either group (Week 0 vs. Week 4; Iron: 625.6 ± 55.5 s vs. 625.4 ± 52.7 s; PLACEBO: 624.8 ± 47.2 s vs. 639.1 ± 59.7 s); but IRON reduced their average time for the 10 × 400 m training session at week 2 (Week 0: 78.0 ± 6.6 s, Week 2: 77.2 ± 6.3; ES-0.20, p = 0.004).
Conclusion: During 6 weeks of training, intravenous iron supplementation improved perceived fatigue and mood of trained athletes with no clinical iron deficiency, without concurrent improvements in oxygen transport capacity or performance.
Databáze: MEDLINE
Externí odkaz: